Resources from the same session
LBA35 - Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial
Presenter: Jean Bourhis
Session: Proffered Paper session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
LBA36 - Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651
Presenter: Athanassios Argiris
Session: Proffered Paper session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
858O - Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC)
Presenter: Anthony T.C. Chan
Session: Proffered Paper session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
859O - Refining TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma: A multicenter cohort study
Presenter: Wang-Zhong Li
Session: Proffered Paper session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
Q&A and live discussion
Presenter: Amanda Psyrri
Session: Proffered Paper session - Head and neck cancer, excl. thyroid
Resources:
Slides
Webcast
Invited Discussant 858O and 859O
Presenter: Lisa Licitra
Session: Proffered Paper session - Head and neck cancer, excl. thyroid
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Lisa Licitra
Session: Proffered Paper session - Head and neck cancer, excl. thyroid
Resources:
Slides
Webcast